

<p>DEPARTMENT OF HEALTH</p> <p><b>No 951</b></p> <p><b>29 September 2006</b></p> <p>EXCLUSION OF CERTAIN MEDICINES FROM THE OPERATION OF CERTAIN PROVISIONS OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965</p> <p><b>401 NO</b></p> <p>101 OF 1965)</p> <p>I, <b>Mandisa Hela, Registrar of Medicines</b>, acting by virtue of a delegation in terms of section 34A of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), hereby exclude in terms of Section 36 of Act 101 of 1965, on the unanimous recommendation of the members present at a meeting of the Medicine Control Council held on <b>11 August 2006</b> the medicines listed in the schedule hereto from the operation of the therein listed provisions of the regulations promulgated by Government Notice No. R.510 of 10 April 2003.</p> <p>.....  <b>MANDISA HELA</b>  <b>REGISTRAR OF MEDICINES</b></p>	<p>DEPARTMENT VAN GEZONDHEID</p> <p><b>No 951</b></p> <p><b>29 September 2006</b></p> <p>UITSLUITING VAN SEKERE MEDISYNE VAN DIE TOEPASSING VAN SEKERE BEPALING VAN DIE WET OP DIE BEHEER VAN MEDISYNE EN VERWANTE STOWWES, 1965 (WET NR. 101 VAN 1965)</p> <p>Ek, <b>Mandisa Hela, Registrateur van Medisyne</b>, handelend kragtens 'n delegasie ingevolge artikel 34A van die Wet op Medisyne en Verwante Stowwe, 1965 (Wet 101 van 1965), en op eenparige aanbeveling van die lede van die Medisynebeheerraad teenwoordig in 'n vergadering gehou op <b>11 August 2006</b>, sluit hierby uit, kragtens Artikel 36 van Wet 101 van 1965, die medisyne in die Bylae hiervan vermeld van die toepassing van die daarinvermelde bepaling van die regulasies afgekondig by Goewermentskennisgewing No. R.510 van 10 April 2003, onderworpe aan die voorwaardes ingelys in the Bylae vermeld.</p> <p>.....  <b>MANDISA HELA</b>  <b>REGISTRATEUR VAN MEDISYNE</b></p>
--	---

REGISTRATION NO/ REGISTRASIE NO	NAME OF MEDICINE/ NAAM VAN MEDISYNE	FORM OF PREPARATION/ BEREIDINGS-VORM	PROVISIONS FROM WHICH EXCLUDED/ BEPALINGS WAARVAN UITGESLUIT	CONDITIONS OF EXCLUSION/ VOORWAAR-DES VIR UITSLUITING	APPLICANT/ APPLIKANT
A400052	10MG/10 ML Platosin 50MG/50 ML		Regulation 8 (1) Labelling of medicines intended for administration to humans (immediate container label): Bilingualism		Pharmachemie
			Regulation 10 (1) Each package of a medicine shall have a patient information leaflet	Provided that the exemption is only applicable to the supply of medicines to 10 patients per year	Boehringer Ingelheim
33/34/0008	Rouvax		Regulation 8 Labelling of medicines intended for administration to humans (immediate container label) (1) Bilingualism (a) Scheduling status (c) Registration number (e) Quantity of each Active ingredient (p) The name of the Holder of Certificate of Registration And Regulation 8 (3) The Council may authorise the inclusion on the label of a medicine of any special information that is not required by this regulation to be so included Aventis Pasteur	Provided that it is only applicable to: a) The Department of Health scheduled measles campaign 2007. b) Aventis to import 700 000 units of Rouvax vaccine for the campaign. c) A once off exemption for the Department of Health measles campaign during 2007.	Aventis Pharma

<p>NX/34/156</p>	<p>Parvolex Injection</p>		<p><i>Regulation 8 Labelling of medicines intended for administration to humans (immediate container label)</i>                  (1) <i>Bilingualism</i>                  (c) <i>Registration number</i>                  (p) <i>The name of the Holder of Certificate of Registration</i></p> <p>And</p> <p><i>Regulation 8 (3) The Council may authorise the inclusion on the label of a medicine of any special information that is not required by this regulation to be so included:</i></p> <ul style="list-style-type: none"> <li>• <i>DBL</i></li> </ul>	<p>Provided that:</p> <p>a) Only a small consignment of 596 packs of 10 units every three to four months imported from the manufacturer in Australia</p>	<p>GlaxoSmithKline</p>
<p>A38/3.2/0562</p>	<p>Bondronat 50</p>		<p><i>Regulation 8 Labelling of medicines intended for administration to humans – Blister foil</i>                  (b) <i>Proprietary name</i></p> <p>And</p> <p><i>Regulation 8 (3) The Council may authorize the inclusion on the label of a medicine of any special information that is not required by this regulation to be so included:</i></p> <p>Authorisation to allow for the Proprietary name to appear as "Bondronat 50mg"                  And for the name of the API to appear in besides English, French or Spanish text.</p>	<p>Provided that:</p> <p>a) the exemption is only applicable for 100 patients per year.</p>	<p>Roche</p>
<p>39/26/0028</p>	<p>Alimta 500mg</p>		<p><i>Regulation 8 Labelling of medicines intended for administration to humans</i></p>	<p>Provided that:</p> <p>a) It is for state</p>	<p>Eli Lilly</p>

		<p>(1) <i>Bilingualism</i>                  (a) <i>Scheduling</i>                  (b) <i>Proprietary name</i>                  (c) <i>Registration number</i>                  (p) <i>Name of the Holder of the Certificate of Registration</i></p> <p>And  <i>Regulation 8 (3)</i>  <i>The Council may authorize the inclusion on the label of a medicine of any special information that is not required by this regulation to be so included:</i></p> <p>Authorisation to allow for information to appear on the "Fix-Form" label in, besides English, French, Dutch, Italian, German or Spanish text and to use the clinical trial label for the donation of the product to the State.</p>			<p>H1088 (Act 101/1<sup>st</sup> 65)                  Unregistered                  Unregistered</p>
				<p>Spongostan                  Sponge                  Spongostan                  Sponge                  Surgiflo                  Haemostatic                  Matrix</p>	
<p>Johnson &amp;                  Johnson</p>	<p>Further, the applicant to be reminded that these products could be in future called up for registration.</p>	<p>Excluded from Section 14(2): Prohibition of sale of medicines that are subject to registration and are not registered.</p>			